NEW YORK (GenomeWeb News) – Clinical Data’s PGxHealth division will provide testing services to PharmaCare Management Services, a large national pharmacy benefits manager, Clinical Data said last week.
Along with testing services, PGxHealth will help the PBM incorporate genetic testing into clinical programs used to select treatment options. Under the agreement, PGxHealth will initially offer clozapine and warfarin tests.
PharmaCare, a wholly owned subsidiary of the chain drug store giant CVS, and Clinical Data will determine other therapeutic areas and disease conditions on which they can collaborate.
PBMs work for big employers, managed care groups, insurance companies, unions, and government agencies. Their main task is to decide what prescription drugs are covered under a given payor program. PharmaCare oversees 30 million patients and is the fourth-largest PBM in the US.
According to Clinical Data, the agreement is a first for the industry. “It illustrates the maturation of the science of pharmacogenomics and the growing awareness of the value of incorporating genetic markers into clinical best practices and quality initiatives,” said Drew Fromkin, the company’s president and CEO, in a statement.
Financial details were not disclosed.